Structural Heart
Transcatheter and percutaneous treatment of valvular and structural heart disease.
View publications →Active Clinical Trials
Active cardiovascular clinical trials at Sentara are currently enrolling and are listed below by therapeutic area.
Structural & Interventional Cardiology 13 trials
- TricValve® Bicaval Valve System for severe tricuspid regurgitation
- Surveillance vs. TAVR for moderate aortic stenosis
- JenaValve Trilogy™ for severe aortic regurgitation in high surgical-risk patients
- Edwards PASCAL transcatheter mitral valve repair pivotal trial
- Cephea Mitral Valve System for symptomatic mitral valve disease
- Percutaneous vs. surgical mitral valve repair for primary mitral regurgitation
- RESTORE — redo TAVR for transcatheter aortic valve failure
- ENCIRCLE — Sapien M3 transcatheter mitral valve replacement (transseptal)
- JenaValve Trilogy™ TAVR for clinically significant AR in patients with LVADs
- APOLLO — Medtronic Intrepid TMVR for severe symptomatic mitral regurgitation
- Impella ECP™ in elective or urgent high-risk PCI
- COSIRA-II — Coronary Sinus Reducer in refractory angina
- Coronary IVL IDE Study (intravascular lithotripsy)
Electrophysiology 8 trials
- Stylet-driven ICD lead for conduction system pacing
- Abbott atrial fibrillation post-approval study
- Conformal CLAAS left atrial appendage occlusion
- OMNY-AF — pulsed field ablation with OMNYPULSE catheter for paroxysmal AF
- CRT using His / left bundle branch pacing vs. biventricular pacing in HF (LVEF ≤ 50%)
- FULCRUM-VT — cryoablation for monomorphic ventricular tachycardia
- FARAPULSE pulsed field ablation in paroxysmal AF (post-approval)
- WATCHMAN FLX™ Pro LAA closure with alternative post-implant monotherapy
Heart Failure & Pulmonary Hypertension 6 trials
- Omecamtiv mecarbil in HFrEF with severely reduced ejection fraction
- RENEU-HF — Phase 2 study of JK07 in chronic heart failure
- Finerenone + SGLT2 inhibitor in patients hospitalized with heart failure
- EASi-HF — Phase III trial of BI 690517 + empagliflozin in HF (LVEF ≥ 40%)
- Pulmonary Hypertension Association Registry
- Pulmonary hypertension screening in interstitial lung disease
Vascular Disease 3 trials
- BD low-profile vascular covered stent in peripheral artery disease
- Low-dose colchicine in PAD for residual vascular risk
- PEERLESS II — FlowTriever vs. anticoagulation alone in pulmonary embolism
For details, eligibility, and to inquire about participation, call 833-866-7766. Each NCT identifier links to the ClinicalTrials.gov record. A complete cardiovascular trial directory is also maintained at Sentara’s research participant portal.
Get Involved
We welcome anyone interested in contributing to our research.
Apply to join